Fig. 1 · Structure

Documents & Downloads

Acadesine (Aicar, NSC 105823)

Cat. No. A10028 CAS 2627-69-2

AMPK activator

Acadesine is a selective activator of AMPK in both hepatocytes and adipocytes.

In Stock

Publications for Acadesine

2 publications citing this product

  1. R. Lim, .et al. , Placenta, 2015, Apr;36(4):454-62 PMID: 25659498
  2. Stella Liong, .et al. , J Physiol Biochem, 2015, Dec;71(4):703-17 PMID: 26407807

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Acadesine (AICAR; AICA riboside) is a cell-permeable riboside used to activate AMPK through intracellular formation of the AMP mimetic ZMP. In HEK293 cells, AICAR activated wild-type AMPK but not an AMP-insensitive γ2 R531G mutant. Its effects are context dependent: AMPK depletion did not rescue the reduction in K562-cell metabolism, and adipocyte glucose-uptake inhibition was not reproduced by the direct AMPK activator 991. These findings limit interpretation of AICAR as a selective AMPK probe. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
AMPK (Cell-free assay)
AMPKK (Cell-free assay)

Cellular Effect

Cell Line Activity Value Description Reference
CCRF-CEM IC50 210 μM Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis [PMID: 24177359]
HCT-116 EC50 > 100 μM Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay [PMID: 36518704]
HCT-116 EC50 > 100 μM Cytotoxicity against human HCT-116 cells overexpressing human MDR1 incubated for 48 hrs by MTT assay [PMID: 36518704]
HCT-116 EC50 > 100 μM Cytotoxicity against human HCT-116 cells overexpressing human BCRP incubated for 48 hrs by MTT assay [PMID: 36518704]
HEK293 EC50 > 100 μM Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay [PMID: 36518704]
HeLa IC50 ≥ 250 μM Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis [PMID: 24177359]
HeLa IC50 165 μM Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis [PMID: 24177359]
K562 IC50 800 μM Cytotoxicity in drug sensitive human K562 cells assessed as reduction cell viability incubated for 48 hrs by XTT assay [PMID: 29655981]
K562 IC50 800 μM Antileukemic activity against human K562 cells after 48 hrs by XTT assay [PMID: 28094938]
K-562R IC50 800 μM Cytotoxicity in imatinib-resistant human K562R cells assessed as reduction cell viability incubated for 48 hrs by XTT assay [PMID: 29655981]
L1210 IC50 ≥ 250 μM Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis [PMID: 24177359]
MDA-MB-231 IC50 1000 μM Anticancer activity against human MDA-MB-231 cells after 48 hrs by XTT assay [PMID: 28325600]
MDA-MB-453 IC50 1700 μM Antiproliferation activity against human MDA-MB-453 cells assessed as reduction in cell viability measured after 4 days by Celltiter-glo luminescent cell viability assay [PMID: 32007387]
RCC4 IC50 250 μM Anticancer activity against human RCC4 cells after 48 hrs by XTT assay [PMID: 28325600]
SK-BR-3 IC50 180 μM Antiproliferation activity against human SK-BR-3 cells assessed as reduction in cell viability measured after 4 days by Celltiter-glo luminescent cell viability assay [PMID: 32007387]

15 records · Scroll to view more

Acadesine (Aicar, NSC 105823) Research Summary

This section summarizes 5 in vitro studies and 1 in vivo study of Acadesine (Aicar, NSC 105823) from 4 published references. In vitro models include K562 cells and purified CD34+ cells from one CML patient; differentiated mouse 3T3-L1 adipocytes.

Acadesine (Aicar, NSC 105823) In Vitro Studies

Reported cellular responses span metabolism and clonogenic growth. Acadesine at 1 mM for 48 h reduced XTT metabolism in CML models, including imatinib-resistant cells, without activating caspase-3 in K562 cells. It also suppressed 10-day CML colony formation. In 3T3-L1 adipocytes, 1 mM AICAR for 24 h inhibited insulin-stimulated glucose uptake by 62 ± 3% (mean ± SEM; n = 11), while basal uptake and GLUT4/HK2 abundance were unchanged. These are model-specific experimental exposures, not recommended working concentrations. [2,3]

AMPK γ2-dependent activation in HEK293 cells

Cell-based study · Isogenic HEK293 cells stably expressing FLAG-tagged wild-type AMPK γ2 or AMP-insensitive γ2 R531G (RG). [1]

AICAR activated AMPK in WT cells but not RG cells. At 3 mM it increased AMPK Thr-172 phosphorylation in WT cells, without a significant rise in ADP:ATP ratio or inhibition of basal oxygen uptake.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AMPK activity after cellular AICAR exposurequalitative response Activation in WT; no activation in RG[1]
AMPK Thr-172 phosphorylationqualitative response Increased in WT; no increase in RG[1]
Cellular ADP:ATP ratio and oxygen uptakequalitative response No significant ADP:ATP increase; no inhibition of basal oxygen uptake[1]

Literature-Reported Treatment Conditions

Treatment concentration
3 mM for phosphorylation, nucleotide and oxygen-uptake experiments; Figure 2D also shows a concentration-response series extending to 10 mM.
Exposure duration
1 h
Method
Cell incubation followed by immunoprecipitation/kinase assay, immunoblotting, capillary electrophoresis or extracellular flux measurement.
Co-treatment
None for the AICAR response; subsequent DNP challenge in oxygen-uptake assay is a separate assay step.
Reported limits
AICAR vehicle not specified in the reviewed methods/legends.
Methods and source locations

Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: AICAR

Literature evidence for acadesine; no Adooq product-use or batch-validation claim.

Results, AICAR response in WT/R531G cells; Figures 2D, 4, 5A, 6A; Experimental Procedures: AMPK assays, nucleotide analysis, oxygen uptake

AMPK activity after cellular AICAR exposure: Anti-FLAG immunoprecipitation; AMARA peptide substrate; activity assayed with 200 µM AMP; mean ± SD, n = 2. — Figure 2D; AMPK Assays

AMPK Thr-172 phosphorylation: Immunoblotting after 3 mM AICAR for 1 h; duplicate incubations. — Figure 4, AICAR panel and legend

Cellular ADP:ATP ratio and oxygen uptake: Capillary electrophoresis: mean ± SD, n = 2 treated, n = 16 controls; oxygen uptake: Seahorse XF24, mean ± SEM, n = 4–10 (AICAR-specific n not separately given). — Figure 5A and legend; Figure 6A and legend

Reduced CML-cell metabolism without caspase-3 activation

Cell-based study · K562, imatinib-resistant K562 (Ima-R), JURL-MK1, LAMA-84 and Ba/F3 cells expressing WT or T315I BCR-ABL. [2]

Acadesine reduced XTT metabolism in the tested CML and Ba/F3 models, including imatinib-resistant cells. In K562 cells, the effect was not rescued by z-VAD-fmk and was not accompanied by caspase-3 activation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Metabolic activity relative to untreated cellsqualitative response Decreased across the tested models[2]
z-VAD-fmk rescue and caspase-3 activationqualitative response No rescue by z-VAD-fmk; no caspase-3 activation with acadesine[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM across the cell-line panel and mechanistic comparisons; Figure 1A additionally tests increasing concentrations through 5 mM in K562.
Exposure duration
48 h
Method
Incubation at 37°C; XTT absorbance at 490 nm; caspase-3 substrate hydrolysis.
Co-treatment
K562 comparison: acadesine 1 mM or imatinib 1 µM, each with or without z-VAD-fmk 50 µM; imatinib is a comparator, not an acadesine combination.
Reported limits
AICAR vehicle not specified in the reviewed methods/legends.
Methods and source locations

Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: Acadesine

Literature evidence for acadesine; no Adooq product-use or batch-validation claim.

Results: Acadesine-Mediated Inhibition of Cell Viability Does Not Involve Apoptosis; Figure 1A–D; Methods: Cell Lines, Measurement of Cell Metabolism, Caspase 3 Activity

Metabolic activity relative to untreated cells: XTT assay; four determinations in quadruplicate described in Figure 1A. No numerical IC50 or graph-derived percentage adopted. — Figure 1A,B and legend

z-VAD-fmk rescue and caspase-3 activation: XTT and Ac-DEVD-AMC hydrolysis; caspase assay uses Ac-DEVD-CHO to establish specificity; four independent experiments in quadruplicate for Figure 1D. — Figure 1C,D and legend

AMPK knockdown does not rescue the K562 metabolic response

Cell-based study · K562 cells with AMPK shRNA versus empty vector, or combined AMPKα1/α2 siRNAs versus control siRNA. [2]

Acadesine increased AMPK phosphorylation, but reducing AMPK expression with either shRNA or siRNAs did not prevent the reduction in XTT metabolism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Rescue of acadesine-induced XTT reduction after AMPK depletionqualitative response No rescue with AMPK shRNA or combined AMPKα1/α2 siRNA[2]
AMPK and S6 ribosomal-protein phosphorylationqualitative response AMPK phosphorylation increased; S6 ribosomal-protein phosphorylation decreased[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM
Exposure duration
48 h of acadesine treatment after 48 h transfection; phosphorylation time course at 2, 6, 24 and 48 h.
Method
Electroporation for shRNA or RNAiMAX for siRNA; immunoblotting and XTT assay.
Co-treatment
Genetic perturbation of AMPK; imatinib 1 µM is a separate comparator in the siRNA experiment.
Reported limits
AICAR vehicle not specified in the reviewed methods/legends.
Methods and source locations

Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: Acadesine

Literature evidence for acadesine; no Adooq product-use or batch-validation claim.

Methods: Sh-RNA Assays and si-RNA Assays; Results: AMPK pathway; Figure 4A–E and legend

Rescue of acadesine-induced XTT reduction after AMPK depletion: Expression depletion checked by immunoblot; metabolism measured by XTT. — Figure 4B–E; shRNA/siRNA methods

AMPK and S6 ribosomal-protein phosphorylation: Immunoblot time course following 1 mM acadesine. — Figure 4A and legend

Suppression of CML colony formation

Cell-based study · K562 cells (0.5×10³ cells/mL in Figure 6A) and purified CD34+ cells from one CML patient (10³ cells/mL). [2]

Acadesine inhibited K562 colony formation across 0.25–2.5 mM. In the single patient-derived CD34+ sample, no colonies were detected at 1 mM after 10 days.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
K562 colony formationqualitative response Inhibition detectable at 0.25 mM; maximal at 2.5 mM[2]
Patient CD34+ colony formationqualitative response No colonies detected at 1 mM[2]

Literature-Reported Treatment Conditions

Treatment concentration
K562: 0.25, 0.5, 1 and 2.5 mM; patient CD34+ cells: 0.25, 0.5 and 1 mM.
Exposure duration
10 days
Method
Semisolid methylcellulose culture; colonies stained with MTT 1 mg/mL and counted with ImageJ.
Co-treatment
Imatinib 1 µM is a separate comparator in the patient CD34+ experiment.
Reported limits
AICAR vehicle not specified in the reviewed methods/legends.
Methods and source locations

Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: Acadesine

Literature evidence for acadesine; no Adooq product-use or batch-validation claim.

Methods: Colony Formation Assay and Primary Cells Isolation; Figure 6A,B and legend; Results: Acadesine Inhibits Tumor Formation

K562 colony formation: Colony counts after 10 days; three determinations in triplicate. — Figure 6A and Results paragraph

Patient CD34+ colony formation: One patient-derived sample; 10-day colony assay. — Figure 6B and Results paragraph

Reduced insulin-stimulated glucose uptake in adipocytes

Cell-based study · Differentiated mouse 3T3-L1 adipocytes. [3]

AICAR inhibited insulin-stimulated glucose uptake without changing basal uptake or GLUT4/HK2 protein abundance. The direct AMPK activator 991 increased ACC phosphorylation but did not reproduce the uptake effect. Adenosine-kinase inhibition with 5-iodotubercidin attenuated the AICAR effect.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of insulin-stimulated [³H]2-deoxyglucose uptake by 1 mM AICARpercent inhibition 62 ± 3%[3]
Basal uptake, GLUT4/HK2 abundance and 991 comparator responsequalitative response Basal uptake unchanged; no observed GLUT4/HK2 change; 991 did not inhibit insulin-stimulated uptake[3]
Effect of 5-iodotubercidin on AICAR-mediated uptake inhibitionqualitative response Significant attenuation of the AICAR effect[3]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM for principal comparisons; 0, 0.5, 1 and 2 mM in the concentration-response experiment.
Exposure duration
24 h pretreatment; insulin stimulation 100 nM for 15 min; radiotracer uptake measured over 3 min.
Method
[³H]2-deoxyglucose uptake and immunoblotting; 3T3-L1 cells used 8–12 days after differentiation.
Co-treatment
Insulin challenge ±100 nM; 991 5 µM is a separate comparator; 5-iodotubercidin 0.1 µM ± AICAR for 24 h in the retained adenosine-kinase inhibitor arm.
Reported limits
AICAR vehicle not specified in the reviewed methods/legends.
Methods and source locations

Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: AICAR

Literature evidence for acadesine; no Adooq product-use or batch-validation claim.

Methods 2.1, 2.3–2.6, 2.9; Results 3.1, 3.5; Figures 1, 2 and 6a,c–e and legends

Inhibition of insulin-stimulated [³H]2-deoxyglucose uptake by 1 mM AICAR: Radiotracer uptake; mean ± SEM; n = 11 independent experiments. — Results 3.1; Figure 1c and legend; Methods 2.6, 2.9

Basal uptake, GLUT4/HK2 abundance and 991 comparator response: GLUT4/HK2 immunoblots n = 3; 991 uptake n = 3; mean ± SEM. — Figures 1c,d, 2 and legends; Results 3.1

Effect of 5-iodotubercidin on AICAR-mediated uptake inhibition: 5-iodotubercidin 0.1 µM; uptake n = 5 independent experiments, mean ± SEM; no exact rescue percentage inferred. — Results 3.5; Figure 6a,c–e and legend

Acadesine (Aicar, NSC 105823) In Vivo Studies

In COX-deficient mice, four weeks of daily subcutaneous AICAR increased muscle cytochrome c oxidase activity. Sco2KO/KI mice receiving 0.25 mg/day/gm body weight showed improved treadmill performance, whereas severely impaired ACTA-Cox15−/− mice receiving 0.5 mg/day/gm showed no functional improvement despite biochemical benefit. The study distinguishes pathway responses from motor efficacy; it does not establish pharmacokinetic exposure or a general endurance benefit. [4]

Biochemical and functional responses in COX-deficient mice

Animal study · Two-month-old Sco2 knockout/knockin (Sco2KO/KI) and muscle-specific ACTA-Cox15−/− mice with appropriate untreated/vehicle controls and WT littermates. [4]

Daily subcutaneous AICAR increased muscle COX activity in both models. Treadmill performance improved in Sco2KO/KI mice but remained unchanged in severely impaired ACTA-Cox15−/− mice. Biochemical improvement therefore did not uniformly translate into functional benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Muscle cytochrome c oxidase activity (pharmacodynamic/biochemical endpoint)qualitative response Increased in treated Sco2KO/KI and ACTA-Cox15−/− mice[4]
Sco2KO/KI motor endurance (functional endpoint)qualitative response Improved; matched WT performance at week 2[4]
ACTA-Cox15−/− motor endurance (functional endpoint)qualitative response No change during treatment[4]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Once daily
Treatment course
4 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Sco2KO/KI, AICAR
0.25 mg/day/gm body weight
Corresponding untreated/vehicle group; WT littermates provide genotype comparison. Vehicle composition not specified.Muscle COX activity increased; treadmill performance improved, reaching WT performance by week 2. Figure 7B: four animals per group.[4]
ACTA-Cox15−/−, AICAR
0.5 mg/day/gm body weight
Corresponding untreated/vehicle group; WT littermates provide genotype comparison. Vehicle composition not specified.Muscle COX activity increased, but treadmill performance did not improve.[4]
Sco2KO/KI, AICAR
Model: Two-month-old Sco2KO/KI mice
Reported limits: Sex and vehicle composition not specified.
ACTA-Cox15−/−, AICAR
Model: Two-month-old muscle-restricted ACTA-Cox15−/− mice
Reported limits: Sex, vehicle composition and exact Figure 7C sample size not specified; Results gives three/four animals per biochemical group.
Methods and source locations

Compound reported in the paper: Acadesine (AICAR; AICA riboside); Compound label in the paper: AICAR

Literature evidence for acadesine; no Adooq product-use or batch-validation claim.

Results: AICAR Induces FAO and OXPHOS Genes; AICAR motor-performance section; Figures 5–7; Experimental Procedures: In Vivo Experiments, Treadmill Test, MRC analysis

Muscle cytochrome c oxidase activity (pharmacodynamic/biochemical endpoint): Spectrophotometry of quadriceps homogenates; no values read off plots. — Results AICAR treatment; Figures 5C and 6C

Sco2KO/KI motor endurance (functional endpoint): Incremental treadmill test; n = 4 per group; mean ± SD; exhaustion defined as >10 falls/min onto motivational grid. — Figure 7B and legend; Treadmill Test methods

ACTA-Cox15−/− motor endurance (functional endpoint): Weekly incremental treadmill testing; SD bars; exact n for Figure 7C not explicitly stated. — Figure 7C and legend; Results motor-performance paragraph

Sco2KO/KI, AICAR · Figures 5 and 7B; AICAR treatment Results; In Vivo Experiments

ACTA-Cox15−/−, AICAR · Figures 6 and 7C; AICAR treatment Results; In Vivo Experiments

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 2627-69-2
Applications AMPK activator
Formula C9H14N4O5
Molecular Weight 258.2
Synonyms AICA-riboside; Aicar; NSC 105823
SMILES
C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 44 mg/mL (170.38 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
5 mg/mL
Vehicle
2% DMSO+40% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Acadesine (Aicar, NSC 105823) Research References

  1. [1] Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell metabolism (2010). PMID: 20519126 DOI: 10.1016/j.cmet.2010.04.001 Source material
  2. [2] Robert G, Ben Sahra I, Puissant A, et al. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PloS one (2009). PMID: 19924252 DOI: 10.1371/journal.pone.0007889 Source material
  3. [3] Alshuweishi Y, Binzomah Alghamdi F, Patrick K, et al. AICAR Inhibits Insulin-Stimulated Glucose Uptake in 3T3-L1 Adipocytes via an AMPK-Independent, ZMP-Dependent Mechanism. Cells (2025). PMID: 41294864 DOI: 10.3390/cells14221811 Source material
  4. [4] Viscomi C, Bottani E, Civiletto G, et al. In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. Cell metabolism (2011). PMID: 21723506 DOI: 10.1016/j.cmet.2011.04.011 Source material

Publications

2 publications citing this product

  1. R. Lim, .et al. , Placenta, 2015, Apr;36(4):454-62 PMID: 25659498
  2. Stella Liong, .et al. , J Physiol Biochem, 2015, Dec;71(4):703-17 PMID: 26407807

Added to your cart

View Cart Checkout
Loading...